Circio Holding ASA (“Circio” or “the Company”) published, on the 28th of October 2026, the materials for its oral and two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg. The materials present a new heart-optimized AAV9 circVec 5.2 design reaching approx. 200x higher gene expression than conventional mRNA-based AAV9, with approx. 95% of the expression occurring in the heart (25%) and less than 1% in the liver (9%).
In summary, Analyst Group views the ESGCT materials as adding precision to the platform’s characterization alongside the step up in heart expression, with the cardiac specificity the most important addition. What remains open is whether the additional protein makes diseased animals better, which the in vivo heart disease-model studies are designed to establish. Circio expects those studies to begin in Q1-27, with read-outs during the year, in line with the six-to-twelve-month guidance given in September, while the R&D webcast at the end of November, presenting in vivo heart and eye results expected to complete during the month, is the nearer-term test.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.